Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy - Completes purchase of ABL Europe SAS from Institut Merieux SA, cementing the partnership between Oxford BioMedica and Institut Merieux. ABL is a cell and gene therapy contract development and manufacturing organization with facilities in Lyon and Strasbourg in France. For the €15 million acquisition, Oxford BioMedica will issue 3.1 million new shares to Lyon-based Institut Merieux at a price of 407.4 pence, well above its current market price. This is a 3.2% stake, and Institut Merieux already had 3.3%, giving it a total 6.5% holding. Oxford BioMedica says Institut Merieux intends to raise this to 10.0% by the end of the September.
Oxford BioMedica says there has been ‘no material change’ to its guidance for 2023 results since its interim results were released in September.
Current stock price: 179.59p, down 0.3% in London on Monday afternoon
12-month change: down 57%
Copyright 2024 Alliance News Ltd. All Rights Reserved.